NECTIN4 and neoplasm: Mice exhibiting low Nectin-4 engagement posttreatment showed reduced tumor growth inhibition, regardless of dose, suggesting that TE itself may serve as a more reliable early biomarker of therapeutic efficacy than dose or Nectin-4 expression alone.